UnitedHealth Beats Q1, Raises Guidance, Stock Jumps 7%
UNH posts EPS of $7.23 vs $6.57 expected and revenue of $111.7B. Medical benefit ratio comes in better than feared at 83.9%.
UnitedHealth just delivered the quarter the bears said was impossible.
The health insurance giant reported Q1 2026 earnings Tuesday morning that crushed expectations across every metric that matters. The stock jumped 7% in premarket trading, adding roughly $35 billion in market value before the opening bell.
This is the same company that crashed 20% in January on Medicare Advantage fears. The turnaround narrative just got real.
The Numbers
| Metric | Actual | Estimate | Beat |
|---|---|---|---|
| EPS (adjusted) | $7.23 | $6.57 | +10% |
| Revenue | $111.72B | $109.57B | +2% |
| Medical Benefit Ratio | 83.9% | 85.5% | 160 bps |
The medical benefit ratio—what UnitedHealth pays out in claims versus premiums collected—was the number everyone watched. Analysts feared rising utilization would push it toward 86%. Instead, claims came in controlled at 83.9%, well below expectations.
Management raised full-year adjusted EPS guidance to more than $18.25 per share, up from $17.75 previously. That's roughly 3% above what the Street had modeled.
Why It Matters
UnitedHealth is the bellwether for managed care. When UNH reports, the entire healthcare sector listens.
The January selloff was driven by two fears: flat Medicare Advantage rates from CMS and rising medical costs as pandemic-deferred care surged back. This quarter addresses both.
Medicare Advantage enrollment actually grew despite the rate pressure. And the medical cost trend—while elevated—came in manageable. The company is passing costs through in premium pricing faster than bears expected.
Optum, the company's healthcare services arm, posted 12% revenue growth. The pharmacy benefits business continued expanding margins. UnitedHealth's diversification strategy is working.
The Turnaround Trade
UNH bottomed near $285 in late January after the Medicare Advantage shock. It closed Monday at $412. This morning's jump takes it toward $440—a 54% rally from the lows.
The stock still trades below its 2024 highs near $520. There's room to run if the cost trends hold.
But one quarter doesn't make a trend. Q2 will face tougher comparisons, and CMS final rates for 2027 come later this year. The company needs to keep executing.
For now, the message is clear: reports of UnitedHealth's demise were exaggerated. The managed care model isn't broken—it was repricing.